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Factors influencing the quality of clinical trials on 
traditional Chinese medicine—Qualitative interviews with 
trial auditors, clinicians and academic researchers
Abstract
Background: As clinical trials evaluating the efficacy of traditional 
Chinese medicine (TCM) therapies have increased, several empirical 
studies have shown that the quality of TCM trials are generally low in 
terms of risk of bias. This qualitative study aimed to investigate the 
factors influencing the quality of TCM clinical trials to provide strategic 
advice on trial quality improvement.
Methods: One focus group with clinical trial auditors (n=4) and six in-
depth semi-structured interviews with clinical research organization 
managers (n=2), lecturers and researchers in TCM academic institutions 
(n=2), a chief physician in a TCM oncology department and a PhD 
candidate specialized in non-pharmaceutical TCM interventions were 
conducted. The interviews were audio-recorded, transcribed verbatim and 
thematically analyzed.
Results: Factors that influenced the quality of TCM clinical trials merged 
on the following 6 themes: trial design; trialists/ participants; trial 
conducting; TCM specified problems; trial monitoring, and finally 
societal influences. The lack of expertise and time inputs of the trialists 
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were repeatedly mentioned. Methodological difficulties experienced 
when conducting TCM trials included calculating sample size, analyzing 
the efficacy of TCM decoctions with multiple ingredients, blinding in 
trials investigating non-pharmaceutical TCM interventions were 
highlighted. Interviewees agreed that third-party monitoring can help 
improving trial quality and improved participant welfare and may 
accelerate recruiting processes and increase compliance; however more 
comprehensive regulations and funding requirements would be needed. 
Conclusions: This study identified real-life issues influencing the quality 
of TCM clinical trials from design to reporting. In addition to mandatory 
training for TCM trial designers and coordinators, more effective 
institutional oversight is required. Future studies should explore specific 
measures to address the methodological problems in TCM trials and 
explore how the quality of TCM trials can affect further evidence 
synthesis and clinical practice.
Keywords: Traditional Chinese medicine (TCM); clinical trial quality; 
randomized controlled trials; qualitative research; influencing factors
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1. Background
Traditional Chinese Medicine (TCM) therapies have been used in 
China for centuries and have attracted increasing attention in the world, 
yet lack of reliable evidence on its effectiveness and safety could be one 
of the impediments for its wider application. Although more and more 
TCM researchers acknowledge the importance of clinical trials [1, 2], 
methodological appraisals and systematic reviews on the published TCM 
clinical trials suggest poor methodological and reporting quality [1, 3, 4], 
pointing out the need for quality improvement.
TCM clinical trials discussed in this study are clinical experiments 
intended to evaluate the efficacy/effectiveness and/or safety of 
interventions (medicinal or nonpharmacologic) based on TCM theories. 
There is an urgent need to ensure the quality of primary research, to 
ensure credibility and reliability of systematic reviews and which should 
be used to inform clinical guidelines on TCM treatments. Primary 
research, alone or synthesized eventually affects clinical practice. 
Understanding the factors influencing the quality of TCM clinical 
trials would be the first step in formulating targeted strategies for 
improvement however the comprehensive research on this question is still 
rare. A few Chinese studies based on questionnaire surveys have reported 
that trial settings[5] and characteristics (such as age, professional titles, 
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years of practice) of the researchers[6] have potential influence on trial 
quality. There are quite a few Chinese papers analyzing the influencing 
factors of trial quality but only based on author’s experiences or opinions 
[7-13] rather than providing qualitative/quantitative evidence. Several 
qualitative studies outside China have tended to focus on a specific phase 
of clinical trials, e.g. trial design or enrollment[14-19] instead of the 
whole process. 
Using qualitative research methods (focus group and in-depth 
interview), this study aimed to investigate factors influencing the quality 
of TCM clinical trials. By interviewing trial designers, key investigators, 
trial coordinators and trial auditors, more detailed information could be 
obtained to understand perceptions and potential barriers to trial quality. 
2. Methods
2.1 Selection of participants
All participants were selected using the homogeneous convenience 
sampling method as described in Jager et al 2017[20]. This approach 
limits the sample to a particular subgroup which gives a homogeneous 
population. Using this method, we restricted our participants to people 
who had taken part in at least one clinical trial on TCM in the previous 5 
years and based in Beijing. XL was in charge of the recruitment.
2.2 Data collection
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One focus group discussion (with 4 participants) and 6 in-depth 
interviews were conducted between March to April 2017. All participants 
provided written consent. All interviews were conducted at the 
workplaces of the participants. Ethical approval was obtained from the 
ethics committee of BUCM (No. 2017BZHYLL0303). 
The semi-structured interview guide was developed after conducting 
a literature review and brainstorming. Three pilot interviews were 
conducted before the guide was finalized. Major questions in the 
interview guide were as follows:
1) Please describe a clinical trial that you are involved with 
currently or previously (no confidential information required).
2) From score 0 to 10, please rate a few clinical trials that you have 
been involved with or read about. Probe all the reasons for the rating.
3) Based on your own experience and understanding, what factors 
may affect the quality of clinical trials? Probe: Why? 
4) What would you say are the main difficulties and problems that 
TCM trials are particularly faced with? What make TCM clinical trials 
different?




All interviews and discussions were audio-recorded and transcribed 
by the authors verbatim. Any private detail concerning individual 
participants was anonymized. Thematic analysis was undertaken [21, 22] 
and open coding was carried out by the authors independently. We then 
categorized the codes, merging redundant or unnecessary codes in the 
process and updated the codebook. Based on the finalized codes, all 
researchers reached an agreement on the coding and themes for the 
transcription. XH, XL and YF led several discussions in which themes 
were synthesized from the codes and quotations[23]. The computer 
software RQDA (R package for qualitative data analysis) was used for 
data storage and analysis.
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FG M.Sci.1 Clinical trial auditor 3 GCP audit Junior2
FG M.Sci. Clinical trial auditor 3 Auditing and trial-site training Junior
FG B.Sci Clinical trial auditor 2 GCP audit Junior
Focus 
Group
FG M.Sci. Clinical trial auditor 6 Auditing and participant recruitment Junior
XL
II-1 M.Sci. CRO manager 7 Clinical trial auditing oversight Middle XL




II-3 M.D. Researcher at China 
Academy of Chinese 
Medical Sciences












10 TCM treatments in oncology; 






II-6 M.D. PhD candidates 
studying at BUCM
NA Non-pharmaceutical TCM treatments Junior
XH
1 M.Sci. stands for master of science.
2 Junior means the participant is a junior title holder.
3. Results
All the people (n=10) we approached agreed to participate in the 
interview and became our participant. Detailed information of 
participants is presented in Table 1. The clinical trial auditor participants 
worked in a contract research organization (CRO) that focused on 
auditing TCM trials. Participant II-3 and II-5 were masters student 
advisers, at a research institute and TCM hospital respectively.
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From the focus group and individual semi-structured interviews, six 
major themes were identified. A total of 32 codes as influencing factors 
emerged (Table 2).
3.1 Trial design
To begin with, most interviewees emphasized that study design has 
major influence on the quality of clinical trials. Whether the trial was 
investigating a clinically important question and whether the methods 
chosen by the trialists were realistic and practical required serious 
consideration. Sometimes due to lack of funding or human resources, 
compromises and change of plans had to be taken into consideration. 
Sample size determination was also highlighted as one of the biggest 
challenges for designing TCM clinical trials.
“The reason why it is so hard to determine the sample size for 
TCM clinical trials is that the effectiveness rates of TCM 
interventions are hard to calculate. Some foreign experts suggest the 
rate should be around 7-8%, but in that way the sample size would be 
more than 1,400—too big for any government funded project.” (II-5)
In addition, the selection of trial centers (for multi-center and large-
scale trials) and identifying appropriate personnel was of critical 
importance. It was also pointed out that when designing the trial, clinical 
trials should consider the inclusion of a management team, so that the 
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quality, progress, financial affairs can be addressed.
“Actually, clinical trials may struggle with managing their 
schedules, regardless of their sources of funding. They always drag 
their feet at the beginning and when the deadline approaches, they 
would rush to the end. That is not helpful for quality assurance.” (II-
2)
3.2 Trialists/ participants
Interviewees remarked that Chinese doctors are often busy being 
Table 2 Factors influencing the quality of TCM clinical trials
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both clinicians and trialists and that puts doctors under great pressure. 
The doctors’ solution was usually to get their “juniors” to do the job. The 
juniors were usually postgraduate students working as interns in the 
hospitals. The interviewees all agreed that many clinical trials were 
actually conducted by these students. The problem is that students were 
shifting between departments and possibly lack of necessary training and 
the sense of responsibility. When the students ended their shift in the 
department, they left the trial duty behind and other people would have to 
take over. The transition process may create many problems. 
“The postgraduate students are not professional trialists. When 
they tried to recruit patients, they are not skillful in getting the 
informed consents. These untrained personnel can cause serious delay 
in participant recruitment and poor patient compliance. The quality 
and progress of the entire trial can be affected.” (FG)
The characteristics of the potential participants also made the trial 
conduct extra challenging.
“The patients seeking medical attention nowadays are mostly 
people in their fifties or sixties. It’s not uncommon for people at this 
age in China to have poor education level due to the Culture 
Revolution in the 1960s and 1970s. This makes communicating with 
them a harder job.” (II-6)
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Interviewees suggested that the clinical trials conducted in hospitals 
should add a research assistant position so that the pressure on the 
practitioners can be partly relieved.
3.3 Conducting the trial
Facilities and equipment at the trial sites can have huge influence on 
the trial too. Although a trial may be primarily conducted in one 
department, the characteristics of the entire research institute has a 
contextual effect on the research quality too. For example, whether the 
laboratory as well as the radiology and diagnostic imaging department in 
the hospital can provide timely results and offer repetitive tests on the 
trial participants. The administrative support and coordination of the 
entire trial facility can be vitally important in this regard.
“Hospitals in the rural areas or primary healthcare facilities are 
willing to conduct clinical trials, but those hospitals lack of the 
necessary equipment for many outcome measurements. Tertiary 
hospitals in metropolises are well equipped but provide a much larger 
service throughput, they can spare few resources for the trial.” (FG)
Some interviewees mentioned that the trial data management and the 
statistical analysis process can be problematic too.
“I think we should regulate the data management process and 
integrate data collection with data analysis. There should be a system 
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which can track every revision or modification on the original data 
and if there is any modification, a sound reason has to be provided.” 
(II-2)
3.4 TCM specific issues
Comparing TCM trials with trials on conventional medicine, two 
kinds of problems should be considered. One was the problems caused by 
the lack of methodological guidance for TCM trials.
“Some TCM studies would stress the traditional ways of data 
collection, which involve quite subjective diagnostic approaches such 
as inspecting, listening, inquiring and pulse taking. There can be very 
little objective data to back up those diagnoses and therefore it’s hard 
to control the quality of those data.” (II-1)
“There are TCM treatments concerns nonpharmacologic TCM 
treatments, such as qigong or Tai Chi. Blinding in a clinical trial 
investigating these therapies is almost impossible.” (II-6)
The other issue was the problems stem from the theoretical 
framework and clinical practice of TCM. For example, the TCM hospitals 
in China were not as mainstream as hospitals specialized in conventional 
medicine, small outpatient visits could translate to increased difficulties 
in participant recruitment. Furthermore, the lack of standards in syndrome 
differentiation and low adherence to clinical guidelines were not only 
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problems in clinical trials but also troublesome in clinical practices.
“Syndrome differentiation is mentioned in many study protocols; 
however, in real practice, clinical practitioners are quite different in 
terms of experience and educational background. The patients from 
northern and southern parts of China can have different body 
constitutions. Thus, the syndrome differentiation can mean different 
things in different trials. That can be very confusing and 
problematic.” (FG)
3.5 Monitoring and auditing
Both the trial auditors and the trialists that were being interviewed 
agreed that introducing a third-party audit team would be helpful for trial 
quality assurance. Nevertheless, the auditors had limitations themselves 
and the monitoring process needed the support and cooperation from the 
trialists.
“We (trial auditors) would see how passive some trialists can be. 
When a problem arises, you expect them to tell you as soon as 
possible, but in fact they won’t even mention it until your next visit to 
the center. Many consequent issues are irreversible till then.” (FG)
“Some trial auditors are not even that qualified themselves. They 
have not been properly trained.” (FG)
Apart from relying on the third-party audit, the trial sites should 
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develop a more rigorous level 1 quality control scheme.
“I noticed that there are quality control divisions in some of the 
trial sites but their monitoring is not very effective. They tend to focus 
more on the paperwork than actual quality assurance.” (II-6)
3.6 Societal influence
Societal factors can have direct impact on patients’ view on clinical 
trials and compliance. Several interviewees mentioned the influence of 
media coverage.
“I saw some news agencies describe clinical trials as some evil 
human experience and compare trial participants to lab mice. I think 
that is not a very objective portrait and it certainly would mislead the 
public to a certain degree.” (FG)
Some requirements in the government funded projects brought 
serious difficulties in the design and conduct of the clinical trials. 
“I think it’s fair to say that if the patients can get more concrete 
benefits from participating the trial, the progress on recruitment and 
the patient compliance would be improved significantly. Some free 
tests or medications or monetary compensations would help a lot.” 
(FG)
“Some projects require the research to improve the curative rate 
of a disease by how much percentage. That’s not a realistic aim for 
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any study, how to measure it for example? And sometimes the 
government is in a big hurry to make progress, asking the clinical 
trials to produce results in 3 years or less. Nobody cares about the 
follow-up issues for trials on chronic diseases.” (II-1; II-5)
Almost all interviewees mentioned in their suggestions for quality 
improvement that there should be budgets granted to pay for research 
assistants and patient compensations in the trial funding. In addition, trial 
sites that are focused more on conducting research than on carrying out 
clinical duties maybe a better place to conduct clinical trials, as the 
trialists would have more time and energy for the research. If the trial 
needs to be conducted in hospitals and by clinicians, trial designers 
should consider balancing the clinical and trial duty for the doctors at the 
protocol developing stage.
4. Discussion
This study explored the factors that influence the quality of TCM 
clinical trials from the perspective of trialists using a qualitative 
approach, i.e. focus group and in-depth interviews. We categorized the 32 
factors identified into 6 themes covering the whole procedure of 
conducting a trial. The interviewees in the study, with experiences of 
different phases of TCM trials as well as various education and academic 
backgrounds, were involved in TCM trials in different ways and offered a 
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wide range of opinions on topic.
Compared with the previous studies, this research used qualitative 
research methods instead of a questionnaire survey or theoretical analysis, 
which allowed us to focus on specific issues of using TCM therapies as 
trial intervention, such as the application of syndrome differentiation. The 
research also explored the designing, conducting, monitoring and 
analyzing clinical trials.
Clinical research on TCM is not so different from trials on 
conventional medicine in terms of the challenges and obstacles they faced 
[22]. Djurisic et al. summarized 6 barriers of conducting RCTs within all 
disease areas as “inadequate knowledge of clinical research and trial 
methodology, lack of funding, excessive monitoring, restrictive privacy 
and lack of transparency, complex regulatory requirements, and 
inadequate infrastructures” [23]. Those barriers are consistent with 
findings of our study except for “excessive monitoring”. Djurisic’s study 
argued that the International Conference on Harmonization (ICH) good 
clinical practice (GCP) guidelines were not required by the law and may 
or may not improve the quality of the trial, yet added huge burdens to the 
trialists [23]. However, in our study the interviewees stressed the 
necessities of trial monitoring. We would recommend increasing 
monitoring and quality control measures over saving funds because the 
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trials in China are often conducted without proper monitoring thus 
causing trial quality problems [4].
Most of our interviewees had found difficulties in designing TCM 
trials to test various research hypotheses as TCM interventions tend to be 
complex and individualized. Better understanding of TCM as well as 
clinical trial methodology was needed to work out the modality suitable 
for TCM trials and its phases. In designing the trial protocol, 
multidisciplinary coordination involving clinical, methodological as well 
as statistical expertise is important[24]. 
Lots of problems were mentioned by the interviewees regarding 
conducting TCM trials. Trialists called for more adequate planning prior 
to the commencement of the trial. Trial registry, as well as the preparation 
and publication of comprehensive protocol and the manual of operations 
should be the new norm among the researchers and these standardized 
procedures will need to be followed. Lack of the expertise in conducting 
trials and poor infrastructure of the trial sites are universal problems [25] 
and can be addressed through better multidisciplinary coordination. For 
TCM trials, profound understanding of TCM theories is additionally 
required. 
Our interviewees strongly emphasized that data authenticity, quality, 
completeness, and timeliness would have significant impact on the trial 
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quality. A 2016 report from China FDA pointed out that 80% of China’s 
clinical trial data were fraudulent [26], indicating the gravity of this issue. 
We suggest a two-pronged strategy for the data management problem: 
one is to enhance the power of the institutional supervising body, building 
the Chinese equivalent of “Data Safety and Monitoring Board” or extend 
the responsibility of the Institutional Review Board or the Ethical 
Committee, now presented in most hospitals and academic institutions in 
China. The institutional oversight can be the first line of defense in data 
integrity; the other is to tackle the incentives for data modification and 
that is related to reporting the trial results to the government and/or to the 
scientific community. 
The limitation of this study was primarily the sample size. However, 
using convenience sampling, we managed to reach a group of participants 
who assuming diversified roles in clinical trials. This enabled us to 
investigate a group of interviewees with different level of trial 
experiences, difference occupations and different roles in trials. Another 
problem with the sample was that since all the participants were recruited 
from Beijing, they may not be representative enough for the trialists in 
China. Nevertheless, Beijing is the capital of China and it has a lot of trial 
sites suitable to conduct clinical research. In addition, some trialists 
participated in this study did travel around the country to supervise the 
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trial sites in other regions. Therefore, we consider this as a valid sample 
for study.
Trial reporting and publication is also important for trial quality as 
clinical evidence, but our study covered very little on this part as we 
mainly focused on the process of trial implementation, and our interview 
did not emphasize this issue. Future study should consider to include 
views from not only the trialists but also other personnel in the industry, 
such as experts on evidence syntheses and grading, editors of medical 
journals, officials who assess and approve funding and together the group 
may unveil more potential challenges and solutions pertaining to the 
quality improvement of clinical trials.
5. Conclusion
This study applied qualitative research methods to explore the 
experiences as well as the point of view of TCM clinical researchers. We 
have identified and categorized the influencing factors of TCM clinical 
trials into 6 themes: trial design; trialists/ participants; trial conducting; 
issues for trials on TCM; monitoring and auditing as well as societal 
influences. The results of this research may attract attention on TCM trial 
quality improvement, and provide a reference point for the prospective 
TCM clinical trials. Future studies may focus on exploring specific 
measures to address the various problems of TCM trials or discovering 
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